Terazosin
Terazosin is an alpha-1 blocker used to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia, or BPH) and high blood pressure.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 52 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Terazosin is an older alpha-1 blocker (on the market since the late 1980s and available as a generic) that relaxes muscle in the prostate and blood vessels, easing urine flow from an enlarged prostate (BPH) and lowering high blood pressure, where it is usually an add-on. Most people settle in well, though dizziness, tiredness and a stuffy nose are common. Watch for a sudden blood pressure drop that can cause fainting, most likely after the first dose, a dose increase or a restart, so take the first dose at bedtime. Tell your prescriber about other blood pressure medicines or erectile dysfunction drugs, which deepen that drop.
Clinical pearls
- Avoid driving or hazardous tasks for 12 hours after the first dose, any dose increase, or a restart.
- If you miss several days in a row, do not restart at your old dose, because the label calls for starting over low.
- Tell your eye surgeon before cataract surgery, since terazosin can cause floppy iris syndrome, which makes the operation harder.
- A painful erection lasting hours is an emergency, so go to an emergency room quickly to prevent permanent impotence.
Patient information guide A plain-language walkthrough of Terazosin, written from its FDA label.
What Terazosin is used for
▾
Terazosin is used for these conditions:
- Symptoms of benign prostatic hyperplasia (BPH): Terazosin capsules and Tezruly oral solution.
- High blood pressure: Terazosin capsules (alone or with other blood pressure medicines) and Tezruly oral solution (adults, alone or with others).
How Terazosin works
▾
Terazosin blocks alpha-1 receptors, which control muscle tightness. In the prostate and bladder neck, this relaxes muscle and eases urine flow. In blood vessels, it lowers resistance and so lowers blood pressure.
Few of these receptors are in the bladder body, so terazosin eases blockage without weakening bladder contraction.
Terazosin dosage
▾
Terazosin is taken by mouth, usually once daily, with the first dose at bedtime. Your prescriber raises the dose slowly based on your symptoms or blood pressure.
- Capsules and Tezruly oral solution have separate labels; follow the instructions for your product.
- For BPH, it may take several weeks at the full dose to judge benefit.
- If you stop for more than a few days, ask before restarting.
Dosing details from the FDA-approved label
From the Terazosin prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Benign prostatic hyperplasia (BPH)
- Initial dose 1 mg at bedtime, which should not be exceeded as an initial dose
- Increase in a stepwise fashion to 2 mg, 5 mg, or 10 mg once daily to achieve the desired improvement of symptoms and/or flow rates
- Doses of 10 mg once daily are generally required for a clinical response
- Treatment with 10 mg for a minimum of 4 to 6 weeks may be required to asses
- Maximum: Insufficient data to support doses higher than 20 mg daily
- If discontinued for more than a few days (several days or longer), restart using the initial dosing regimen; follow patients closely during initial administration
- Hypertension
- Initial dose 1 mg at bedtime, which should not be exceeded
- Slowly increase to achieve the desired blood pressure response
- Usual recommended dose range is 1 mg to 5 mg once a day
- Some patients may benefit from doses as high as 20 mg per day
- If response is substantially diminished at 24 hours, consider an increased dose or a twice daily regimen
- Dose inter
- Maximum: Doses over 20 mg do not appear to provide further blood pressure effect; doses over 40 mg have not been studied
- If discontinued for more than a few days (several days or longer), restart using the initial dosing regimen; Tezruly oral solution may be taken with or without food
Read the label’s full dosing text
2 DOSAGE & ADMINISTRATION For the treatment of BPH: Initiate therapy at 1 mg orally once daily at bedtime. Titrate the dose upwards step-wise from 2 mg to 10 mg once daily. Doses of 10 mg once daily are generally required for a clinical response. Data is insufficient to support doses greater than 20 mg once daily. (2.1) For the treatment hypertension: Initiate therapy at 1 mg orally once daily at bedtime. Usual recommended dose range is 1 mg to 5 mg once daily. If response is substantially diminished at 24 hours, increase the dose or use twice daily. Dose may be titrated as needed up to 20 mg once daily. (2.2) If terazosin is discontinued for more than a few days, restart using the initial dosing regimen. (2.1) 2.1 Recommended Dosage for Benign Prostatic Hyperplasia Initial Dose: 1 mg orally once daily at bedtime. This dose should not be exceeded as an initial dose. Closely follow patients during initial administration in order to minimize the risk of severe hypotensive response, including syncope. For administration instructions, see Dosage and Administration (2.3). Subsequent Doses: The dose should be increased in a stepwise fashion from 2 mg to 10 mg orally once daily to achieve the desired improvement of symptoms and/or flow rates. Doses of 10 mg once daily are generally required for a clinical response. Therefore, treatment with 10 mg for a minimum of 4 weeks to 6 weeks may be required to assess whether a beneficial response has been achieved. Although some patients responded to 20 mg per daily, data are insufficient to draw definitive conclusions about this dose. There are insufficient data to support the use of doses higher than 20 mg daily. If TEZRULY is discontinued for more than a few days, therapy should be restarted using the initial dosing regimen. For administration instructions, see Dosage and Administration (2.3). 2.2 Recommended Dosage for Hypertension Initial Dose: 1 mg orally once daily at bedtime. Do not exceed the initial dosing regimen to minimize the potential for severe hypotensive effects, including syncope. For administration instructions, see Dosage and Administration (2.3). Subsequent Doses: Slowly increase the dose to achieve the desired blood pressure response. The usual recommended dose range is 1 mg to 5 mg orally once daily; however, some patients may benefit from doses as high as 20 mg per day.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Terazosin side effects
▾
Most side effects are mild to moderate. Common ones include:
Common side effects
- Dizziness
- Weakness or tiredness
- Drowsiness
- Stuffy nose
- Nausea
- Palpitations (pounding heartbeat)
- Swelling in the legs or feet
- Blurred vision
When to get medical help
- Fainting or feeling like you may pass out, especially after the first dose, a dose increase, or restarting
- Painful erection lasting hours that does not go away: go to an emergency room right away
- Racing or irregular heartbeat
- Severe dizziness or lightheadedness when standing
- Signs of a serious allergic reaction, such as trouble breathing or swelling
- Tell your eye surgeon you take terazosin if you plan cataract surgery
Terazosin warnings and precautions
▾
- Fainting and low blood pressure: highest risk in the first 7 days, with dose increases, or after restarting.
- Priapism: rare, but needs emergency care.
- Cataract surgery: tell your eye surgeon you take terazosin.
- Prostate cancer: should be ruled out before treating BPH.
Terazosin interactions
▾
Some medicines add to terazosin's blood pressure lowering.
- Other blood pressure medicines, especially verapamil: can cause too-low blood pressure.
- PDE-5 inhibitors: can cause low blood pressure; they should start at the lowest dose.
Interactions listed in the FDA-approved label
From the Terazosin prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Other antihypertensive agents, especially the calcium channel blocker verapamil: Concomitant use carries the possibility of developing significant hypotension. Observe caution; dosage reduction and retitration of either agent may be necessary.
- Phosphodiesterase-5 (PDE-5) inhibitors: Hypotension has been reported when terazosin was used with PDE-5 inhibitors.
- Verapamil (pharmacokinetic study, n = 24): Terazosin mean AUC 0-24 increased 11% after the first verapamil dose and by 24% after 3 weeks of verapamil, with Cmax up 25% and Cmin up 32%; terazosin mean Tmax decreased from 1.3 hours to 0.8 hours. No statistically significant differences in verapamil level with and without terazosin.
- Captopril (study, n = 6): Plasma disposition of captopril was not influenced by terazosin, and terazosin maximum plasma concentrations increased linearly with dose at steady-state with captopril.
- Diuretics and beta-adrenergic blockers: In controlled trials terazosin was added to diuretics and several beta-blockers; no unexpected interactions were observed.
- Analgesic/anti-inflammatory agents (e.g., acetaminophen, aspirin, codeine, ibuprofen, indomethacin): Used concomitantly in at least 50 patients; no interactions were observed.
- Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole): Used concomitantly in at least 50 patients; no interactions were observed.
- Anticholinergic/sympathomimetics (e.g., phenylephrine, phenylpropanolamine, pseudoephedrine): Used concomitantly in at least 50 patients; no interactions were observed.
- Sedatives and tranquilizers (e.g., diazepam): Used concomitantly in at least 50 patients; no interactions were observed.
- Antigout agents (e.g., allopurinol), antihistamines (e.g., chlorpheniramine), corticosteroids, gastrointestinal agents (e.g., antacids), hypoglycemics: Used concomitantly in at least 50 patients; no interactions were observed.
Read the label’s full interactions text
Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine, ibuprofen, indomethacin). 2) antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole). 3) anticholinergic/sympathomimetics (e.g., phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride). 4) antigout (e.g., allopurinol). 5) antihistamines (e.g., chlorpheniramine). 6) cardiovascular agents (e.g., atenolol, hydrochlorothiazide, methyclothiazide, propranolol). 7) corticosteroids. 8) gastrointestinal agents (e.g., antacids). 9) hypoglycemics. 10) sedatives and tranquilizers (e.g., diazepam). Use with Other Drugs In a study (n = 24) where terazosin and verapamil were administered concomitantly, terazosin's mean AUC 0-24 increased 11% after the first verapamil dose and after 3 weeks of verapamil treatment it increased by 24% with associated increases in C max (25%) and C min (32%) means. Terazosin mean T max decreased from 1.3 hours to 0.8 hours after 3 weeks of verapamil treatment. Statistically significant differences were not found in the verapamil level with and without terazosin. In a study (n = 6) where terazosin and captopril were administered concomitantly, plasma disposition of captopril was not influenced by concomitant administration of terazosin and terazosin maximum plasma concentrations increased linearly with dose at steady-state after administration of terazosin plus captopril (see DOSAGE AND ADMINISTRATION ).
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Terazosin
▾
- Do not take it if allergic to terazosin or its ingredients.
- Tell your doctor about pregnancy or breastfeeding; data are limited.
- Not established for children.
- Older adults clear it more slowly.
- Kidney impairment did not significantly affect elimination.
Terazosin overdose
▾
Overdose can cause low body temperature, slow heart rate, and low blood pressure. Management focuses on supporting the heart and circulation, including lying flat. Dialysis is unlikely to help. Call Poison Control at 1-800-222-1222.
What Terazosin does in the body
▾
Terazosin relaxes smooth muscle in the prostate and bladder neck, improving urine flow and symptoms without weakening bladder contraction. In studies, symptoms and peak flow improved from about week 2 and stayed improved over long-term use. In men with normal blood pressure, it did not lower blood pressure meaningfully.
How your body processes Terazosin
▾
Tezruly reaches peak blood levels in under an hour, and food did not make a clinically significant difference. Terazosin is highly protein bound and has a half-life of about 13 hours. It is mostly unchanged in the blood, and about 60% leaves in the feces and 40% in the urine.
How to store Terazosin
▾
Dispense in a tight, light-resistant container as defined in the USP. Store at 20° - 25°C (68° - 77°F) . Protect from light and moisture.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Terazosin
137 supplements and herbal products have documented interactions with Terazosin in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 4
- Moderate · 112
- Minor · 21
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Terazosin has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Terazosin: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Terazosin — the kind of thing our pharmacy team would talk through with you at the counter.
What is terazosin for?
▾
Why do I take the first dose at bedtime?
▾
What if I miss several days?
▾
What side effects are common?
▾
Can I take it with erectile dysfunction medicines or other blood pressure pills?
▾
Is there anything urgent to watch for?
▾
Is Terazosin available over the counter?
▾
When was Terazosin first available?
▾
Who makes Terazosin?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Terazosin on HelloPharmacist
Terazosin forms and strengths (how it comes)
Terazosin is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Terazosin inactive ingredients by manufacturer.
Capsule
How this form is used
- Terazosin capsules are used to treat symptomatic BPH.
- Terazosin capsules are also used to treat high blood pressure, alone or with other blood pressure medicines.
- Terazosin capsules start at bedtime, with the dose raised gradually.
- For high blood pressure, the dosing interval (12 or 24 hours) is adjusted to your blood pressure response.
- If terazosin capsules are stopped for several days, therapy should be restarted with the initial regimen.
Oral solution
How this form is used
- Tezruly is used for symptoms of BPH in adult men.
- Tezruly is used to lower blood pressure in adults with high blood pressure, alone or with other blood pressure medicines.
- Tezruly is started once daily at bedtime and raised step by step.
- Tezruly showed no clinically significant differences in absorption after a high-fat meal.
- If Tezruly is stopped for more than a few days, restart using the initial regimen.
Terazosin on the U.S. market: products, makers and brands
How Terazosin appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
20 companies list 88 Terazosin product records with the FDA, mostly as capsule, oral solution; the earliest marketing or approval year on record is 1987. Brand names on the directory include Hytrin, Tezruly; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (7) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Terazosin is used (Medicaid data)
A general measure of how commonly Terazosin is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Terazosin is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Terazosin prescribed? Of the 1,601 medications we measure, Terazosin ranks #588 by Medicaid prescriptions — more than 63% of them.
Utilization by Terazosin product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
terazosin 2 MG Oral Capsule Most dispensed
Summed across the 5 of 85 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 313217
terazosin 5 MG Oral Capsule
Summed across the 5 of 73 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 313219
terazosin 1 MG Oral Capsule
Summed across the 5 of 61 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 313215
terazosin 10 MG Oral Capsule
Summed across the 4 of 61 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 260376
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Terazosin, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 19 of 280 listed Terazosin NDCs with Medicaid activity.
Compare Terazosin products
A representative set of FDA-listed product records for Terazosin — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 1 mg | Oral | A-S Medication Solutions × 2 listings | ANDA | View NDC → |
| 2 mg | Oral | A-S Medication Solutions | ANDA | View NDC → |
| 5 mg | Oral | A-S Medication Solutions | ANDA | View NDC → |
| 10 mg | Oral | A-S Medication Solutions | ANDA | View NDC → |
| 1 mg | Oral | Ajanta Pharma USA Inc. | ANDA | View NDC → |
| 2 mg | Oral | Ajanta Pharma USA Inc. | ANDA | View NDC → |
| 5 mg | Oral | Ajanta Pharma USA Inc. | ANDA | View NDC → |
| 10 mg | Oral | Ajanta Pharma USA Inc. | ANDA | View NDC → |
| 1 mg | Oral | Amerisyn, LLC | ANDA | View NDC → |
| 2 mg | Oral | Amerisyn, LLC | ANDA | View NDC → |
| 5 mg | Oral | Amerisyn, LLC | ANDA | View NDC → |
| 10 mg | Oral | Amerisyn, LLC | ANDA | View NDC → |
| 1 mg | Oral | Amerisyn LLC | ANDA | View NDC → |
| 2 mg | Oral | Amerisyn LLC | ANDA | View NDC → |
| 5 mg | Oral | Amerisyn LLC | ANDA | View NDC → |
| 10 mg | Oral | Amerisyn LLC | ANDA | View NDC → |
| 1 mg | Oral | Amici Pharma, Inc. | ANDA | View NDC → |
| 2 mg | Oral | Amici Pharma, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Amici Pharma, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Amici Pharma, Inc. | ANDA | View NDC → |
| 1 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC × 4 listings | ANDA | View NDC → |
| 2 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC × 3 listings | ANDA | View NDC → |
| 5 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC × 3 listings | ANDA | View NDC → |
| 10 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC × 2 listings | ANDA | View NDC → |
| 1 mg | Oral | Apnar Pharma LP | ANDA | View NDC → |
| 2 mg | Oral | Apnar Pharma LP | ANDA | View NDC → |
| 5 mg | Oral | Apnar Pharma LP | ANDA | View NDC → |
| 10 mg | Oral | Apnar Pharma LP | ANDA | View NDC → |
| 1 mg | Oral | AvKARE | ANDA | View NDC → |
| 2 mg | Oral | AvKARE | ANDA | View NDC → |
| 5 mg | Oral | AvKARE | ANDA | View NDC → |
| 10 mg | Oral | AvKARE | ANDA | View NDC → |
| 1 mg | Oral | AvPAK | ANDA | View NDC → |
| 2 mg | Oral | AvPAK | ANDA | View NDC → |
| 5 mg | Oral | AvPAK | ANDA | View NDC → |
| 10 mg | Oral | AvPAK | ANDA | View NDC → |
| 1 mg | Oral | Bionpharma Inc. | ANDA | View NDC → |
| 2 mg | Oral | Bionpharma Inc. | ANDA | View NDC → |
| 5 mg | Oral | Bionpharma Inc. | ANDA | View NDC → |
| 10 mg | Oral | Bionpharma Inc. | ANDA | View NDC → |
| 1 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 2 mg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | Bryant Ranch Prepack × 3 listings | ANDA | View NDC → |
| 10 mg | Oral | Bryant Ranch Prepack × 5 listings | ANDA | View NDC → |
| 1 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 2 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 5 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 10 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 5 mg | Oral | Coupler LLC | ANDA | View NDC → |
| 1 mg | Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | ANDA | View NDC → |
| 2 mg | Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | ANDA | View NDC → |
| 5 mg | Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | ANDA | View NDC → |
| 10 mg | Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | ANDA | View NDC → |
| 1 mg | Oral | Jubilant Cadista Pharmaceuticals Inc. | ANDA | View NDC → |
| 2 mg | Oral | Jubilant Cadista Pharmaceuticals Inc. | ANDA | View NDC → |
| 5 mg | Oral | Jubilant Cadista Pharmaceuticals Inc. | ANDA | View NDC → |
| 10 mg | Oral | Jubilant Cadista Pharmaceuticals Inc. | ANDA | View NDC → |
| 2 mg | Oral | Northwind Health Company, LLC | ANDA | View NDC → |
| 2 mg | Oral | NuCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 1 mg | Oral | Preferred Pharmaceuticals, Inc | ANDA | View NDC → |
| 2 mg | Oral | Preferred Pharmaceuticals, Inc | ANDA | View NDC → |
| 5 mg | Oral | Preferred Pharmaceuticals, Inc | ANDA | View NDC → |
| 2 mg | Oral | Preferred Pharmaceuticals Inc. × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | Proficient Rx LP | ANDA | View NDC → |
| 10 mg | Oral | Proficient Rx LP | ANDA | View NDC → |
| 1 mg | Oral | Remedyrepack Inc. × 2 listings | ANDA | View NDC → |
| 2 mg | Oral | Remedyrepack Inc. × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | Remedyrepack Inc. | ANDA | View NDC → |
| 💊Oral solution | ||||
| 1 mg/mL | Oral | ANI Pharmaceuticals, Inc. | NDA | View NDC → |
Showing 88 of 88 products — FDA National Drug Code Directory. See every product, package size and price: browse all 88 Terazosin NDCs →
Terazosin side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Terazosin — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Terazosin in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Terazosin FDA approval history
How Terazosin went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Terazosin recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Terazosin recalls since July 2021.
✅No Terazosin recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 37798 3 dose forms · 9 strengths
-
Dose form (SCDF) Oral Capsule RxCUI 374033In current FDA listings -
Dose form (SCDF) Oral Solution RxCUI 2689132In current FDA listingsClinical drug / strength (SCD) 1 MG/MLRxCUI 2689133 -
Dose form (SCDF) Oral Tablet RxCUI 374034No current FDA listingClinical drug / strength (SCD) 1 MGRxCUI 3132162 MGRxCUI 3132185 MGRxCUI 31322010 MGRxCUI 313214
Look up RxCUI 37798 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Terazosin supply and shortage status
Whether Terazosin is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Terazosin costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Capsule · Oral | 2 mg | $0.106 per capsule | NDC details & price history |
| Capsule · Oral | 5 mg | $0.108 per capsule | NDC details & price history |
| Capsule · Oral | 10 mg | $0.130 per capsule | NDC details & price history |
| Capsule · Oral | 1 mg | $0.108 per capsule | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Terazosin brand names
Terazosin is sold under 2 brand names in the FDA directory — Hytrin, Tezruly. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Terazosin: manufacturers and labelers
20 companies list Terazosin products with the FDA. By number of product records, the largest are Aphena Pharma Solutions - Tennessee, LLC, Bryant Ranch Prepack, Amerisyn LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Terazosin drug class (RxNorm)
Terazosin belongs to the alpha-Adrenergic Blocker class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Terazosin page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. ANI Pharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →